PULMATRIX, INC. Operating Lease, Liability, Noncurrent
PULMATRIX, INC. (PULM) had Operating Lease, Liability, Noncurrent of $8.23 million as of 2024-03-31, per its 10-Q filed 2024-05-10.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OperatingLeaseLiabilityNoncurrent · last filed 2025-03-21
- 2024-03-31: Operating Lease, Liability, Noncurrent $8.23M.
- 2023-12-31: Operating Lease, Liability, Noncurrent $8.33M.
- 2023-09-30: Operating Lease, Liability, Noncurrent $8.42M.
- 2022-03-31: Operating Lease, Liability, Noncurrent $430.00K.
| Period end | Operating Lease, Liability, Noncurrent |
|---|---|
| 2024-03-31 | $8.23M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $8.33M 10-K · filed 2025-03-21 |
| 2023-09-30 | $8.42M 10-Q · filed 2023-11-09 |
| 2022-03-31 | $430.00K 10-Q · filed 2022-05-12 |
| 2021-12-31 | $857.00K 10-K · filed 2023-03-30 |
| 2021-03-31 | $306.00K 10-Q · filed 2021-05-11 |
| 2020-12-31 | $608.00K 10-K · filed 2022-03-29 |
| 2020-09-30 | $898.00K 10-Q · filed 2020-11-12 |
| 2020-06-30 | $1.18M 10-Q · filed 2020-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |